COHERENT VIEW OF NON-HODGKINS-LYMPHOMA

被引:103
作者
AISENBERG, AC
机构
[1] Hematology/Oncology Unit, Massachusetts General Hospital, Boston, MA
[2] Massachusetts General Hospital, Boston, MA 02114, Fruit St
关键词
D O I
10.1200/JCO.1995.13.10.2656
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Even though non-Hodgkin's lymphoma is already sixth in incidence and mortality among malignant neoplasms (and the incidence was increasing at a rate of 3% to 4% per year before the advent of AIDS epidemic-associated lymphomas), most physicians and many oncolgists find the disorder arcane. The problem lies in the complexity of human lymphoma, which encompasses more than a dozen neoplasms of the lymphoid system, The goal of this review is to provide user-friendly access to the condition, Methods: The variety of inputs required for a subdivision of non-Hodgkin's lymphoma that is useful to clinicians includes lymphocyte lineage and sublineage based on microscopic appearance and immunophenotype, clinical behavior manifest in survival and early dissemination, and analysis of molecular generic and cytogenetic abnormalities, which reflect pathogenic oncogene derangements, Epstein-Barr virus (EBV) and human T-cell leukemia virus type 1 (HTLV-I) ore important in certain uncommon lymphomas, Results and Conclusion: The subtypes of primary B-lineage nodal lymphoma include low-grade (small lymphocytic, lymphoplasmacytic-lymphoplasmacytoid, follicular small cleaved cell, and follicular mixed small cleaved and large cell), intermediate-grade (follicular large cell, diffuse small cleaved or mixed, and intermediate lymphocytic), and high-grade (diffuse large cell, immunoblastic, and small noncleaved cell) neoplasms. The less common lymphomas of T lineage and lymphomas that arise in extranodal sites are placed in separate subdivisions, This subdivision serves as a guide to prognosis and treatment. (C) 1995 by American Society of Clinical Oncology.
引用
收藏
页码:2656 / 2675
页数:20
相关论文
共 211 条
  • [1] ABE M, 1992, CANCER, V70, P821, DOI 10.1002/1097-0142(19920815)70:4<821::AID-CNCR2820700417>3.0.CO
  • [2] 2-Y
  • [3] THE C-MYC ONCOGENE DRIVEN BY IMMUNOGLOBULIN ENHANCERS INDUCES LYMPHOID MALIGNANCY IN TRANSGENIC MICE
    ADAMS, JM
    HARRIS, AW
    PINKERT, CA
    CORCORAN, LM
    ALEXANDER, WS
    CORY, S
    PALMITER, RD
    BRINSTER, RL
    [J]. NATURE, 1985, 318 (6046) : 533 - 538
  • [4] AISENBERG AC, 1991, MALIGNANT LYMPHOMA B
  • [5] LONG-TERM FOLLOW-UP OF PATIENTS TREATED WITH COMP OR LSA2L2 THERAPY FOR CHILDHOOD NON-HODGKINS-LYMPHOMA - A REPORT OF CCG-551 FROM THE CHILDRENS CANCER GROUP
    ANDERSON, JR
    JENKIN, RDT
    WILSON, JF
    KJELDSBERG, CR
    SPOSTO, R
    CHILCOTE, RR
    COCCIA, PF
    EXELBY, PR
    SIEGEL, S
    MEADOWS, AT
    HAMMOND, GD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (06) : 1024 - 1032
  • [6] CLINICAL-FEATURES AND PROGNOSIS OF FOLLICULAR LARGE-CELL LYMPHOMA - A REPORT FROM THE NEBRASKA-LYMPHOMA-STUDY-GROUP
    ANDERSON, JR
    VOSE, JM
    BIERMAN, PJ
    WEISENBURGER, DD
    SANGER, WG
    PIERSON, J
    BAST, M
    ARMITAGE, JO
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (02) : 218 - 224
  • [7] ANDERSON T, 1982, CANCER-AM CANCER SOC, V50, P2708, DOI 10.1002/1097-0142(19821215)50:12<2708::AID-CNCR2820501203>3.0.CO
  • [8] 2-G
  • [9] PRIMARY MALIGNANT-LYMPHOMA OF THE THYROID - A TUMOR OF MUCOSA-ASSOCIATED LYMPHOID-TISSUE - REVIEW OF 76 CASES
    ANSCOMBE, AM
    WRIGHT, DH
    [J]. HISTOPATHOLOGY, 1985, 9 (01) : 81 - 97
  • [10] ARMITAGE JO, 1989, CANCER, V63, P158, DOI 10.1002/1097-0142(19890101)63:1<158::AID-CNCR2820630125>3.0.CO